Eli Lilly and Co (NYSE:LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other ...
(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 billion, granting Lilly access to its AI-driven platform to discover and develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback